Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics ...

INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston ...

Eli Lilly's stock showed surprising stability, with minimal movement despite significant pipeline developments. The ...

A backlash against a White House video promoting deportation and Casalonga opening a new office in Düsseldorf were also among the top talking points ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the Stocks With Huge Catalysts on the Horizon. On April 14, Verve ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...

Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...

Source: Bloomberg, data from to 31 March 2025 to 30 June 2025. Returns are for the MSCI All Country World Index (ACWI) and its 11 sectors. The MSCI ACWI Index captures large- and mid-cap ...